Figure 2
Figure 2. Resiquimod is an effective therapy for early-stage CTCL. Changes from baseline of CAILS (A) and SWAT scores (B) are shown for the 12 patients treated. Patient numbers are shown below each bar and the dosage of topical resiquimod is indicated by bar color. Nine of 12 patients had a 50% or greater improvement from baseline of treated lesions among and 4 cleared all treated target lesions during therapy. Eleven of 12 patients experienced improvement of 50% or more in total surface area of involvement from baseline as assessed by SWAT score analysis, with 2 patients experiencing complete clearing of all evidence of disease. CR, complete remission; PR, partial remission; SD, stable disease.

Resiquimod is an effective therapy for early-stage CTCL. Changes from baseline of CAILS (A) and SWAT scores (B) are shown for the 12 patients treated. Patient numbers are shown below each bar and the dosage of topical resiquimod is indicated by bar color. Nine of 12 patients had a 50% or greater improvement from baseline of treated lesions among and 4 cleared all treated target lesions during therapy. Eleven of 12 patients experienced improvement of 50% or more in total surface area of involvement from baseline as assessed by SWAT score analysis, with 2 patients experiencing complete clearing of all evidence of disease. CR, complete remission; PR, partial remission; SD, stable disease.

Close Modal

or Create an Account

Close Modal
Close Modal